Le Lézard
Classified in: Health, Science and technology
Subjects: Conference, Webcast

MindMed to Participate at May Investor Conferences


Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that members of the Company's management team will participate in the following investor conferences:

An audio webcast and replay of the fireside chat at the 2024 RBCCM Global Healthcare Conference will be accessible on MindMed's Investor Relations website for up to 90 days following the event.

About MindMed

MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed trades on NASDAQ under the symbol MNMD.


These press releases may also interest you

at 17:00
Zepp Health Corporation Reports First Quarter 2024 Unaudited Financial Results
Zepp Health Corporation ("Zepp" or the "Company") today reported revenues of US$39.8 million; a basic and diluted net loss per share of US$0.06; and a basic and diluted net loss per ADS of US$0.23 for the first quarter ended March 31, 2024;...

at 17:00
Yalla Group Limited Announces Unaudited First Quarter 2024 Financial Results
Yalla Group Limited ("Yalla" or the "Company") , the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today announced its unaudited financial results for the first quarter ended March 31, 2024. First...

at 16:56
JDRF-Authored Paper Shows Pathway to Accelerate Disease-Modifying Therapies for People with Type 1 Diabetes
A paper published in the June edition of the Journal Diabetes demonstrates that C-peptide, a biomarker that indicates the production of insulin, is a validated surrogate endpoint, or predictor of clinical benefit, for clinical trials of...

at 16:42
Karman Space & Defense Launches New Website & Tagline
Karman Space & Defense ("Karman"), a concept-to-production solutions provider for the most complex challenges in our industry, proudly announces the launch of its captivating, newly redesigned website, and bold tagline "Impossible Ends Here."...

at 16:35
Nordson Corporation Reports Second Quarter Fiscal 2024 Results and Updates Annual Guidance
Nordson Corporation today reported results for the fiscal second quarter ended April 30, 2024. Sales were $651 million, comparable to the prior year's second quarter sales of $650 million. The second quarter 2024 sales included a favorable...

at 16:30
SHI International Corp. Announces Definitive Agreement to Acquire Locuz Enterprise Solutions Limited, an Indian Cybersecurity and Digital Transformation Services Company
SHI International Corp., a leading global provider of innovative technology solutions, today announced that it has entered into a definitive agreement to acquire Locuz Enterprise Solutions Limited, an Indian cybersecurity and digital transformation...

More news about Science and technology...


News published on and distributed by: